The present invention is directed to nifuratel sulfoxide. In particular, it is directed to the use of nifuratel sulfoxide, or a physiologically acceptable salt thereof, or a physiologically acceptable cocrystal thereof, to treat bacterial infections and, in particular, to treat infections caused by Atopobium and Gardnerella species. The invention is further directed to the use of nifuratel sulfoxide to treat bacteriuria, urinary tract infections, infections of external genitalia in both sexes, as well as bacterial vaginosis, or mixed vaginal infections in women, when one or more species of the genera Atopobium and Gardnerella are among the causative pathogens of those infections.text
